Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function

Tony J. Zheng, Elizabeth R. Lofurno, Alexander R. Melrose, Hari Hara Sudhan Lakshmanan, Jiaqing Pang, Kevin G. Phillips, Meghan E. Fallon, Tia C.L. Kohs, Anh T.P. Ngo, Joseph J. Shatzel, Monica T. Hinds, Owen J.T. McCarty, Joseph E. Aslan

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (BTK) play critical roles in platelet physiology, facilitating intracellular immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling downstream of platelet glycoprotein VI (GPVI) and GPIIb/IIIa receptors. Small molecule tyrosine kinase inhibitors (TKIs) targeting Syk and BTK have been developed as antineoplastic and antiinflammatory therapeutics and have also gained interest as antiplatelet agents. Here, we investigate the effects of 12 different Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. These inhibitors include four Syk inhibitors, Bay 61-3606, R406 (fostamatinib), entospletinib, TAK-659; four irreversible BTK inhibitors, ibrutinib, acalabrutinib, ONO-4059 (tirabrutinib), AVL-292 (spebrutinib); and four reversible BTK inhibitors, CG-806, BMS-935177, BMS-986195, and fenebrutinib. In vitro, TKIs targeting Syk or BTK reduced platelet adhesion to collagen, dense granule secretion, and alpha granule secretion in response to the GPVI agonist crosslinked collagen-related peptide (CRP-XL). Similarly, these TKIs reduced the percentage of activated integrin αIIbβ3 on the platelet surface in response to CRP-XL, as determined by PAC-1 binding. Although all TKIs tested inhibited phospholipase Cγ2 (PLCγ2) phosphorylation following GPVI-mediated activation, other downstream signaling events proximal to phosphoinositide 3-kinase (PI3K) and PKC were differentially affected. In addition, reversible BTK inhibitors had less pronounced effects on GPIIb/IIIa-mediated platelet spreading on fibrinogen and differentially altered the organization of PI3K around microtubules during platelets spreading on fibrinogen. Select TKIs also inhibited platelet aggregate formation on collagen under physiological flow conditions. Together, our results suggest that TKIs targeting Syk or BTK inhibit central platelet functional responses but may differentially affect protein activities and organization in critical systems downstream of Syk and BTK in platelets.

Original languageEnglish (US)
Pages (from-to)C902-C915
JournalAmerican Journal of Physiology - Cell Physiology
Issue number5
StatePublished - May 2021


  • BTK
  • Ibrutinib
  • Platelet
  • Syk
  • Tyrosine kinase

ASJC Scopus subject areas

  • Physiology
  • Cell Biology


Dive into the research topics of 'Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function'. Together they form a unique fingerprint.

Cite this